0001493152-21-029889.txt : 20211124
0001493152-21-029889.hdr.sgml : 20211124
20211124193714
ACCESSION NUMBER: 0001493152-21-029889
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211022
FILED AS OF DATE: 20211124
DATE AS OF CHANGE: 20211124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bausch Christoph Lawrence
CENTRAL INDEX KEY: 0001889981
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39871
FILM NUMBER: 211448796
MAIL ADDRESS:
STREET 1: 2100 E 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001833214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 853899721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 W. 41ST STREET
STREET 2: SUITE 202
CITY: MIAMI BEACH
STATE: FL
ZIP: 33140
BUSINESS PHONE: (305) 204-3338
MAIL ADDRESS:
STREET 1: 300 W. 41ST STREET
STREET 2: SUITE 202
CITY: MIAMI BEACH
STATE: FL
ZIP: 33140
FORMER COMPANY:
FORMER CONFORMED NAME: Big Cypress Acquisition Corp.
DATE OF NAME CHANGE: 20201120
4/A
1
ownership.xml
X0306
4/A
2021-10-22
2021-10-26
0
0001833214
SAB Biotherapeutics, Inc.
SABS
0001889981
Bausch Christoph Lawrence
2100 E 54TH STREET NORTH
SIOUX FALLS
SD
57104
0
1
0
0
Chief Science Officer
Employee Stock Option (right to buy)
0.50
2021-10-22
4
A
0
104689
A
2027-03-12
Common Stock
104689
104689
D
Employee Stock Option (right to buy)
0.50
2021-10-22
4
A
0
81425
A
2027-03-12
Common Stock
81425
81425
D
Earnout Rights (Restricted Stock Units)
2021-10-22
4
A
0
108086
A
Common Stock
108086
108086
D
Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
The option is fully vested.
Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]
25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.
This Form 4 amendment amends the Form 4 filed by the reporting person on October 26, 2021. This amendment is being filed to correct the expiration date of the employee stock options and the expiration date of the earnout rights.
/s/ Christoph Lawrence Bausch
2021-11-24